This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The 5 Dumbest Things on Wall Street This Week: Oct. 25

1. Repros Rebuke

The brains behind Repros Therapeutics (RPRX) are clearly not beyond reproach.

Shares of Repros tumbled nearly 30% to around $17 Wednesday after the company admitted that the FDA has raised concerns about the reliability of some of the clinical data collected during the phase III studies of its testosterone boosting drug Androxal. These are the Androxal studies, in case you may have forgotten, in which Repros admitted that one enrolling site fabricated clinical data, while another collected anomalous data due to Gay Cuban men having too much sex.

Yeah, we know. It's hard to forget our friends at good old Repros, but unlike CEO Joe Podolski, we like to cover all our bases.

And as TheStreet's biotech ax Adam Feuerstein alertly points out, it's also the same good old Repros which just last month assured investors that the FDA would find nothing wrong with the clinical data supporting Androxal. In the same release, Podolski added, "We are confident in the reliability of our results and the positive outcome of our two clinical trials."

Podolski's September promise about the high quality of the Androxal data helped Repros shares climb to four-year high. Repros, which by the way has no revenue, is now trading where it did in June, before the big biotech summer rally began.

Nevertheless, just because the stock gave up its gains doesn't mean it's cheerleaders on Wall Street are giving up the ghost.

Lazard analyst Josh Schimmer told clients in a note that "the slight delay to tighten Androxal filing is worthwhile." Meanwhile, Brean Capital analyst Jon Aschoff blew off the FDA's concerns and said the latest Androxal data twist "could be positive in the end."

Of course, they very well could be proven right in the long run.

Until Repros offers more proof to back up its claims, however, all we can offer back to Repros is a reproof.

-- Written by Gregg Greenberg in New York

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
5 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs